

Appointment of New Company Secretary and General Counsel

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: **RHY**) (**Rhythm** or the **Company**) wishes to advise that, in accordance with ASX Listing Rule 3.16.1, the Company is pleased to announce the appointment of Ms Andrea Steele as General Counsel & Company Secretary, with immediate effect.

Ms Steele has a Bachelor of Laws (LLB), a Master of Laws (LLM), a Master of Legal Practice and a Bachelor of Commerce (Accounting / Finance).

Her professional career spans over 23 years and includes management consultancy positions throughout Europe and Australia, Corporate Strategy Analyst at IWL Limited (ASX: IWL) and Corporate Strategy and Company Secretary at Investorfirst Ltd (now ASX: HUB). More recently, Ms Steele's roles include General Counsel and EGM – Retail & Regulatory Affairs at WINconnect Pty Ltd. Currently Ms Steele is a Principal Consultant at ENRG Consulting.

The Board have acknowledged that the Company is entering a transition stage toward further regulatory approvals and commercialisation (including partnering agreements), thus the requirement for additional, complementary skill sets has been identified in line with the evolution of the business.

The Company's previous joint Company Secretaries, Mr Adrien Wing and Ms Pauline Moffatt have formally resigned from their roles as Joint Company Secretaries, effective 25 February 2022, in order to pursue other business initiatives. Despite these formal resignations, both Ms Moffatt and Mr Wing have offered to continue to provide support services to the Company on an as needed basis.

The Board gratefully acknowledges Mr Wing and Ms Moffatt for their important service and contribution to the Company since its' inception. Mr Wing, in particular, was instrumental in the founding of the Company. He played key roles in negotiations with CSIRO for the acquisition of the core technology underlining ColoSTAT®, in establishing Rhythm's initial Board and in overseeing its listing onto the ASX in December 2017. The Company warmly wish Mr Wing and Ms Moffatt well in their pursuit of alternate business endeavours.

Entities involved with Mr Wing remain a substantial shareholder of the Company and are supportive of the Company's strategy and growth trajectory. These entities have no current intention to sell shares in the Company.

For the purposes of ASX listing rule 12.6, RHY wishes to confirm that Ms Steele will be the person responsible for communications between the Company and ASX.

- ENDS -

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

www.rhythmbio.com

Australian Registered Address
Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

T +61 3 8256 2880
E info@rhythmbio.com

Directors
Otto Buttula
Glenn Gilbert
Trevor Lockett
Rachel David
Louis Panaccio
Eduardo Vom

Executive Chairman
Managing Director
Executive Director
Non-Executive Director
Non-Executive Director
Non-Executive Director

Authorised for release by the Board.

For further information contact:

Glenn Gilbert
CEO and Managing Director
+61 3 8256 2880

About Rhythm Biosciences

Rhythm Biosciences is focused on becoming a globally significant, transformative, predictive diagnostics company, specialising in cancer detection technology. The Company is currently developing ColoSTAT[®] - a simple, low-cost, blood test for global mass market detection of colorectal cancer.

Worldwide, colorectal cancer is the third most common cancer in men and the second most common in women, accounting for an estimated 1.9 million new cases and 935,000 deaths annually.

In an effort to reduce the global burden, many countries have implemented screening programs aimed at early detection. These programs are predominantly administered with a faecal immunochemical test (FIT) for the assessment of colorectal cancer risk, with a positive result referred for a colonoscopy. FIT only analyses the presence of blood in faeces, which can occur for several reasons other than cancer, therefore it is not designed as an accurate test for cancer. Many people simply don't take the test for fear of an unnecessary colonoscopy procedure, unpleasantness, difficulty, or for religious/cultural reasons. There is currently no appropriate blood test alternative.

Rhythm aims to transform the global mass-market for colorectal cancer detection with ColoSTAT[®] its simple, low-cost blood test that is fit for purpose, meaning that it is designed to actually detect colorectal cancer. Since listing on the ASX in 2017, the Company has run a successful multi-year research and development program that has delivered technical validation of the core biomarker technology, being reproducible and stable. The ColoSTAT[®] test-kit was manufactured in 2021 and delivered performance testing that outperforms the current market standard faecal immunochemical test (FIT) utilising Rhythm's proprietary algorithm. The Company is currently finalising its clinical trial for ColoSTAT[®], and is progressing regulatory, manufacturing and scale up activities ahead of market entry in 2022.

ColoSTAT[®] is designed to be used easily by laboratories without the need for additional operator training or additional infrastructure. ColoSTAT[®] has the potential to play a key role in reducing the morbidity and mortality rates and healthcare costs associated with colorectal cancer via increasing current screening rates.

Rhythm's initial targeted global addressable population is over 800 million people which are over 50 years of age. Almost 70%, or 550 million people, are not currently screened for colorectal cancer due to the limitations of the current faecal based testing regime. This "at risk" population is also expanding with the disease growing rapidly in much younger age groups. Early detection and intervention can lead to cure in over 90 per cent of new cases, therefore the need for effective screening and early intervention has the potential to save a significant number of lives. Rhythm estimates today's colorectal cancer screening market alone to be worth in excess of \$38 billion.